Eureka Therapeutics
PrivateLast Round
Grant
Jun 6, 2023
Total Funding Raised
$136.6M
Company Overview
Eureka Therapeutics operates in Healthcare & Life Sciences and is based in Emeryville, California. Its latest recorded funding round was a Grant round in June 2023.
Eureka Therapeutics is a biotechnology company that develops novel T-cell therapies and antibody-drug discovery technology for the treatment of solid tumors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Eureka Therapeutics Comparables
Compare Eureka Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Crossbow Therapeutics | 82% | |
| Oricell Therapeutics | 81% | |
| A2 Biotherapeutics | 80% |
For institutional investors. Book with your work email.
Eureka Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jun 6, 2023 | ||||
| Series E | Mar 17, 2020 | ||||
| Series D | Jan 22, 2018 | ||||
| Series C | Sep 23, 2014 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Eureka Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Acorn Campus Ventures | Series D, Series C |
| Suma Venture | Series C, Series D |
| California Institute for Regenerative Medicine | Grant |
| Yuan Capital | Series D, Series C |
| Harbinger Venture Capital | Series C, Series D |
| 金浦产业投资基金管理有限公司 | Series D |
| Acorn Pacific Ventures | Series D |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Dec 22, 2025
Added Iwai Chem, a chemicals/distribution SMB, as a customer.
- Aug 12, 2025
William S. Solari III has joined the Board of Directors.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingNov 3, 2026
Eureka Therapeutics, a clinical-stage biotechnology company in California, is developing novel T-cell therapies for solid tumors, including ARTEMIS® programs in Phase I/II trials and programs developed with the National Cancer Institute.
- is_developingNov 3, 2026
In collaboration with the National Cancer Institute, Eureka Therapeutics develops ARTEMIS(R) T-cell therapies targeting mesothelin for pancreatic cancer and other MSLN-expressing solid tumors in California as of Nov 3rd '26.
For institutional investors. Book with your work email.
Eureka Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Eureka Therapeutics's valuation, stock price, and market status.
Is Eureka Therapeutics a public or private company?
Eureka Therapeutics is a private company.
What is the current stock price of Eureka Therapeutics?
Eureka Therapeutics is a private company, so its shares have no public market price. Caplight tracks Eureka Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Eureka Therapeutics worth (valuation)?
Valuation information for Eureka Therapeutics is not publicly available.
Can I buy Eureka Therapeutics stock?
Eureka Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Eureka Therapeutics's last funding round?
Eureka Therapeutics's most recent funding round was Grant on June 6, 2023.
Who are the main investors in Eureka Therapeutics?
Key investors in Eureka Therapeutics include Yuan Capital, Acorn Pacific Ventures.
Will Eureka Therapeutics IPO soon?
No public IPO plans have been announced for Eureka Therapeutics.
How can I track Eureka Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Eureka Therapeutics's shares on secondary markets.